Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 6/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.61 |
| ▸ | PAK1 | Q13153 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720729 | 0.89 | CYP2C9 (0.66) | CYP2C9CYP3A4PAK1CYP2C19NTRK1 | |
| SCHEMBL2351343 | 0.85 | CYP2C9 (0.48) | CYP2C9CYP3A4PAK1CYP2C19NTRK1 | |
| SCHEMBL299665 | 0.84 | CYP3A4 (0.61) | CYP2C9CYP3A4PAK1CYP2C19BRAF | |
| SCHEMBL299382 | 0.83 | BRAF (0.51) | CYP2C9CYP3A4PAK1CYP2C19NTRK1 | |
| SCHEMBL3705469 | 0.83 | CYP3A4 (0.52) | CYP2C9CYP3A4PAK1CYP2C19BRAF | |
| SCHEMBL2883747 | 0.83 | CYP2C9 (0.46) | CYP2C9CYP3A4PAK1CYP2C19NTRK1 | |
| SCHEMBL2357075 | 0.83 | BRAF (0.49) | CYP2C9CYP3A4PAK1CYP2C19BRAF | |
| SCHEMBL15667244 | 0.82 | CYP2C9 (0.60) | CYP2C9CYP3A4PAK1CYP2C19 | |
| SCHEMBL1086020 | 0.82 | CYP2C9 (0.44) | CYP2C9CYP3A4PAK1NTRK1 | |
| SCHEMBL3506675 | 0.81 | AXL (0.58) | CYP2C9PAK1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-09-27 | — | — | US | claimed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | claimed |
| WO-2010129567-A1 | PYRROLO [2, 3. B] PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | claimed |
| US-20100286178-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2010-11-11 | — | — | US | claimed |
| WO-2010104945-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2010-09-16 | — | — | WO | claimed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-06-08 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20100286178-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286178-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129567-A1 | PYRROLO [2, 3. B] PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010104945-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010104945-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CYP2C9 871/4885CYP3A4 1288/4885PAK1 2576/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | CYP2C9 4816/4885CYP3A4 4591/4885PAK1 1972/4885 |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, PRKACA, MAP3K13 | CYP2C9 4771/4885CYP3A4 4679/4885PAK1 179/4885 |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | CYP2C9 4771/4885CYP3A4 4679/4885PAK1 179/4885 |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, ARAF, RAF1 | CYP2C9 2237/4885CYP3A4 2892/4885PAK1 40/4885 |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DDOST, DAD1, PHGDH | CYP2C9 4097/4885CYP3A4 3525/4885PAK1 2397/4885 |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, RAF1 | CYP2C9 2237/4885CYP3A4 2892/4885PAK1 40/4885 |
| US-20100286178-A1 | COMPOUNDS AND USES THEREOF | BRAF, RAF1, FER | CYP2C9 2194/4885CYP3A4 3815/4885PAK1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.